英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

CrApTeX    
/krap'tekh/ (University of York, England) Term of abuse used
to describe {TeX} and {LaTeX} when they don't work (when used
by TeXhackers), or all the time (by everyone else). The
non-TeX enthusiasts generally dislike it because it is more
verbose than other formatters (e.g. {troff}) and because
(particularly if the standard Computer Modern fonts are used)
it generates vast output files.

See {religious issues}.

[{Jargon File}]

(1994-12-01)


请选择你想看的字典辞典：
单词字典翻译
CrApTeX查看　CrApTeX　在百度字典中的解释百度英翻中〔查看〕
CrApTeX查看　CrApTeX　在Google字典中的解释Google英翻中〔查看〕
CrApTeX查看　CrApTeX　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Navepegritide (Yuviwel®) for Children with Achondroplasia . . .
    Navepegritide (Yuviwel®) for Children with Achondroplasia: New Drugs and Therapeutics Written by Anna Ryabets-Lienhard, DO Edited by Neha Patel, DO and Emily Breidbart, MD On February 27th, 2026, the FDA approved Navepegritide (Yuviwel®), a C-natriuretic peptide (CNP) analog prodrug developed by Ascendis Pharmaceuticals using TransCon® CNP technology 1 The once‑weekly subcutaneous therapy
  • FDA Approves Navepegritide for Children With Achondroplasia
    The FDA has approved navepegritide (Yuviwel; Ascendis Pharma) for children aged 2 years and older with achondroplasia and open growth plates under the agency's Accelerated Approval Program, according to a news release from Ascendis Pharma The once-weekly subcutaneous injection represents the first achondroplasia therapy designed to provide continuous systemic exposure to C-type natriuretic
  • FDA Approves Once-Weekly YUVIWEL® (navepegritide) for . . .
    “The approval of once-weekly YUVIWEL is a major step forward in the treatment of children with achondroplasia, giving physicians for the first time the option of prescribing a once-weekly medicine backed by compelling efficacy and excellent tolerability data from three randomized, double-blind, placebo-controlled clinical trials,” said
  • Once-Weekly Navepegritide in Children With Achondroplasia
    Meaning Navepegritide treatment resulted in significantly greater linear growth and similar safety and tolerability compared to placebo in children with achondroplasia, with additional benefits beyond growth, including improved skeletal alignment and body proportionality, and positive changes in health-related quality of life
  • Once-weekly TransCon CNP (navepegritide) in children with . . .
    However, an unmet need remains for a treatment that improves the additional medical complications arising from achondroplasia TransCon CNP (navepegritide) is an investigational prodrug of CNP designed to provide sustained release of CNP supporting continuous exposure with a once-weekly dosing regimen
  • Once-Weekly Navepegritide Safe and Efficacious for . . .
    Bacino highlights the recently approved treatment’s safety data and emphasizes the likelihood of increased adherence due to longer intervals between administration On February 27, 2026, the US Food and Drug Administration (FDA) approved Ascendis Pharma’s navepegritide treatment for achondroplasia in children, under the name Yuviwel 1
  • FDA accepts navepegritide application to treat children with . . .
    On June 2, 2025, the FDA accepted a new drug application for navepegritide (TransCon CNP; Ascendis Pharma A S) to treat children with achondroplasia and has assigned a Prescription Drug User Fee Act date of November 30, 2025, for potential approval The investigational prodrug of C-type natriuretic peptide (CNP) is administered once weekly and designed to treat individuals living with
  • Yuviwel FDA Approval: Once‑Weekly CNP for Achondroplasia
    Overview Yuviwel (navepegritide) is a once‑weekly, subcutaneous C‑type natriuretic peptide (CNP) analog approved by the U S Food and Drug Administration in February 2026 to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses [1, 2] Developed by Ascendis Pharma as TransCon CNP, Yuviwel is a PEGylated prodrug that releases native CNP
  • FDA Grants Accelerated Approval to Yuviwel (navepegritide . . .
    Ascendis Submits U S NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - March 31, 2025 Yuviwel (navepegritide) FDA Approval History FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals
  • FDA approves once-weekly medication to increase growth in . . .
    The FDA has approved a once-weekly therapy to improve growth for children aged 2 years and older with achondroplasia, according to an industry press release Navepegritide (Yuviwel, Ascendis Pharma





中文字典-英文字典  2005-2009